MIME Symposium 2024
| Event Name | MIME Symposium 2024 |
|---|---|
| Start Date | Oct 31, 2024 12:30 pm |
| End Date | Oct 31, 2024 6:00 pm |
| Duration | 5 hours and 30 minutes |
| Description | Whether you’re starting your journey as a medical technology innovator, like the majority of our partners at MIME through Monash University and our Monash Partners clinical networks, or well advanced in the pathway towards solving your unmet need and achieving clinical impact, at some stage you will almost certainly need to raise funds. This might be a small or large grant, philanthropy or investment from a myriad of other sources. Join our symposium to listen to and talk with our expert panel, where we’ll discuss all things MedTech investment. Our panellists have significant experience being and working with university and hospital-based researchers and clinicians. They collectively bring expertise in digital health and medical device development and investment, with expertise both in sourcing and distributing funding. Meet our keynote
Dr Santosh Kaur Dr Santosh Kaur is a doctor, nurse, AI researcher and founder of SmartHeal - point of care wound healing platform. With over 17 years in health care across two countries, her extensive experience ranges from leading major hospital departments to working in operation theatre to senior roles in aged care. She has also worked as a registered clinician for the Aged Care Quality and Safety Commission and a clinical advisor (secondment) for the Commonwealth Government. Hear Santosh's inspiring story from doctor, to aged care nurse, and eventually founding her company, here. Meet our panellists
Ashley Ng Dr Ashley Ng is a diabetes advocate and researcher. Her experience and career have stemmed from her lived experience advocacy journey within Australia and internationally. She is currently the project manager and research fellow at Monash Partners and Monash Centre for Health Research and Implementation (MCHRI) for a MRFF funded project to better support the adoption of consumer and community involvement across healthcare improvement and health research. Her areas of interest include use of Health technology, co-designing diabetes education programs to support diabetes technology use and best practice consumer and community involvement.
Grace Lethlean As a co-inventor on a patented and ASX listed digital health technology; Grace Lethlean has been actively involved in the development of health technologies from invention, through clinical trials, to commercialisation. Grace is co-founder and Chief Product Officer of ANDHealth, Australia’s national digital health initiative, accelerating the commercialisation of evidence-based digital health technologies. Grace’s focus is on supporting digital health technologies to meet key investor, partner and customer requirements around clinical and commercial validation. Grace also supports the sector through numerous state and national Advisory Panels and Committees, is a 2020SuperStar of STEM, is an inventor on patents in the US and Australia, a published author on digital health commercialisation, and a 2022 Churchill Fellow, investigating international best practice in digital health business support.
Patricia Rueda Patricia joined Brandon Capital in 2022, as an analyst for the National Biotech Incubator CUREator where she supports the translation of early stage biomedical innovation across the country. Previously, Patricia worked as Corporate Development Manager at oNKo-innate, a discovery-stage biotechnology company dedicated to immune-oncology target identification and therapeutic development. Previous to this role, Patricia worked as project manager on the drug discovery collaboration between Monash institute of Pharmaceutical Sciences (MIPS) and pharma company Servier, investigating novel modes of regulation of GPCRs in an effort to identify novel targets or approaches for drug discovery. Through her professional career, Patricia has gained experience in translational project management, advancing projects for the development of diverse modalities targeting different therapeutic areas, and at different stages of the drug discovery process, from early target validation to late lead optimization phase. Additionally, she developed skills needed for commercial target/project analysis, critical to her current Analyst role as part of the CUREator team. Patricia received her education and performed her graduate studies at the University of Jaen in Spain, continuing her training as a postdoc at the Parisian Institute Pasteur, gaining critical skills and experience that prepared her for her career in drug discovery and biomedical research and development.
Pat Kelly Pat Kelly is a seasoned entrepreneur with three successful company exits. Pat co-founded and is CEO of Remagine Labs, which is developing a wearable electro-pharmaceutical drug delivery device for the treatment of epilepsy and other chronic conditions. Remagine Labs was recently awarded a $3M CRC-P grant in partnership with the University of Melbourne, Monash University, and AK Clinical Research. Prior to Remagine, Pat was co-founder and CEO of Nitero, a Data61 spinout which developed wireless Virtual and Augmented Reality (V/AR) solutions. Nitero was sold to Advanced Micro Devices (AMD) in 2017.
Paul Carboon Paul is an experienced Founder, Board member, CEO and Project Manager with extensive product development and commercialisation experience, across a wide range of technologies and industries, specialising in MedTech. Paul has completed the Australian Institute of Directors Course, CEO Master class and many certifications in project management including PMBOK. Meet our Session Chairs
Robert Crowder Robert Crowder is MIME’s Lead Consultant on our MCAP program. With deep experience in consulting and medical device development, Rob works with companies early on to help them define the right product and commercial strategy for their new intervention. He is a key conduit between business, clinical and engineering teams and skilled in distilling complex principles and ideas into practical action. With experience across the full life cycle of medical device commercialisation, Rob is a trusted advisor for companies in determining clinical utility and value for their new venture.
Jordan Thurgood Jordan has a strong passion for research commercialisation in particular in the engineering and health/wellbeing sectors. Jordan is a founder and inventor listed on several patents, including granted US patents. After co-founding 4Dx (now ASX:4DMedical) during his PhD, he worked at Monash Innovation, helping Monash researchers commercialise their inventions, including spinning out companies. Currently, he is the CEO of Strength By Numbers, which develops technology for monitoring physical human strength and performance. Jordan holds a PhD in Engineering from Monash University and is a graduate of the Australian Institute of Company Directors.
Professor Carol Hodgson Professor Carol Hodgson is Executive Director of Monash Partners Academic Health Science Centre, Head of the Division of Clinical Trials and Cohort Studies in the School of Public Health and Preventive Medicine, and Deputy Director of the Australian and New Zealand Intensive Care Research Centre, Monash University. She has held NHMRC or Heart Foundation funding throughout her career, currently with an Investigator Grant (2020-2024). She is a Specialist Physiotherapist in Intensive Care at The Alfred Hospital, Melbourne, Australia. She is a Fellow of the Australian Academy of Health and Medical Science and of the Australian College of Physiotherapists. She has expertise in rehabilitation and long-term outcomes of critically ill patients, and the use of invasive life support such as mechanical ventilation and extracorporeal membrane oxygenation (ECMO). |
